Citigroup’s Cellectis CLLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3 | Sell |
1
-2,557
| -100% | -$9.8K | ﹤0.01% | 5805 |
|
|
2025
Q4 | $12.4K | Buy |
2,558
+1,568
| +158% | +$6.55K | ﹤0.01% | 4996 |
|
|
2025
Q3 | $2.82K | Buy |
+990
| New | +$2.56K | ﹤0.01% | 5404 |
|
|
2023
Q1 | – | Sell |
-263
| Closed | -$552 | – | 5543 |
|
|
2022
Q4 | $552 | Buy |
263
+10
| +4% | +$23 | ﹤0.01% | 5493 |
|
|
2022
Q3 | $1K | Sell |
253
-71
| -22% | -$215 | ﹤0.01% | 5610 |
|
|
2022
Q2 | $1K | Sell |
324
-35,424
| -99% | -$125K | ﹤0.01% | 5991 |
|
|
2022
Q1 | $162K | Sell |
35,748
-7,790
| -18% | -$42.9K | ﹤0.01% | 4185 |
|
|
2021
Q4 | $354K | Sell |
43,538
-9,995
| -19% | -$98.2K | ﹤0.01% | 4026 |
|
|
2021
Q3 | $675K | Sell |
53,533
-6,081
| -10% | -$84.2K | ﹤0.01% | 3403 |
|
|
2021
Q2 | $922K | Buy |
59,614
+51,889
| +672% | +$872K | ﹤0.01% | 3297 |
|
|
2021
Q1 | $156K | Buy |
7,725
+3,351
| +77% | +$82.9K | ﹤0.01% | 4142 |
|
|
2020
Q4 | $118K | Sell |
4,374
-3,075
| -41% | -$69K | ﹤0.01% | 5401 |
|
|
2020
Q3 | $138K | Sell |
7,449
-19
| -0.3% | -$337 | ﹤0.01% | 4879 |
|
|
2020
Q2 | $133K | Buy |
7,468
+6,156
| +469% | +$93.7K | ﹤0.01% | 5331 |
|
|
2020
Q1 | $12K | Sell |
1,312
-219
| -14% | -$3.27K | ﹤0.01% | 6955 |
|
|
2019
Q4 | $26K | Buy |
1,531
+883
| +136% | +$11.8K | ﹤0.01% | 6795 |
|
|
2019
Q3 | $7K | Buy |
648
+64
| +11% | +$861 | ﹤0.01% | 7207 |
|
|
2019
Q2 | $9K | Buy |
584
+154
| +36% | +$2.75K | ﹤0.01% | 7334 |
|
|
2019
Q1 | $8K | Buy |
430
+230
| +115% | +$4.08K | ﹤0.01% | 7302 |
|
|
2018
Q4 | $3K | Sell |
200
-3,000
| -94% | -$69.5K | ﹤0.01% | 7446 |
|
|
2018
Q3 | $90K | Hold |
3,200
| – | – | ﹤0.01% | 6007 |
|
|
2018
Q2 | $91K | Sell |
3,200
-45
| -1% | -$1.34K | ﹤0.01% | 5810 |
|
|
2018
Q1 | $102K | Sell |
3,245
-235
| -7% | -$7.42K | ﹤0.01% | 5597 |
|
|
2017
Q4 | $101K | Buy |
3,480
+3,280
| +1,640% | +$89.3K | ﹤0.01% | 5628 |
|
|
2017
Q3 | $6K | Buy |
+200
| New | +$5.17K | ﹤0.01% | 6810 |
|
|
2016
Q2 | – | Sell |
-37
| Closed | -$1K | – | 7106 |
|
|
2016
Q1 | $1K | Buy |
37
+35
| +1,750% | +$843 | ﹤0.01% | 7280 |
|
|
2015
Q4 | $0 | Sell |
2
-157
| -99% | -$4.76K | ﹤0.01% | 7585 |
|
|
2015
Q3 | $4K | Buy |
+159
| New | +$5.32K | ﹤0.01% | 6805 |
|
|
2015
Q2 | – | Sell |
-50
| Closed | -$2K | – | 7540 |
|
|
2015
Q1 | $2K | Buy |
+50
| New | +$1.81K | ﹤0.01% | 6923 |
|
Other funds holding CLLS
BGI
LFCM
NAMI
Citigroup's CLLS Position: Q1 2026 in Review
Citigroup reduced its Cellectis (CLLS) stake by 100% in Q1 2026, selling an estimated $9.8K and leaving 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #5805.
Citigroup first reported a position in CLLS in Q1 2015 and has held it in 29 quarters since. The position peaked at $922K in Q2 2021. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.
- Citigroup held 1 share of Cellectis worth $3 as of Q1 2026.
- Citigroup sold 2,557 Cellectis shares in Q1 2026, an estimated $9.8K.
- Cellectis made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5805 holding.
- Citigroup first reported a position in Cellectis in Q1 2015 and has held it in 29 quarters since.
- Citigroup's Cellectis position peaked at $922K in Q2 2021.
- 32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.